Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pangaea OncologyXMAD:PANG 61 PB Ratio is 2.61 as of Jul. 26, 2026, which is 6% below its 10-year median of 2.78. GuruFocus rates XMAD:PANG with a GF Score™ of 61/100 and a GF Value™ of €2.18 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 60.82% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-26), Pangaea Oncology's share price is €1.55. Pangaea Oncology's Book Value per Share for the quarter that ended in Dec. 2025 was €0.59. Hence, Pangaea Oncology's PB Ratio of today is 2.61.
The historical rank and industry rank for Pangaea Oncology's PB Ratio or its related term are showing as below:
XMAD:PANG'
s PB Ratio Range Over the Past 10 Years
Min: 1.95 Med: 2.78 Max: 5.82
Current: 2.61
During the past 13 years, Pangaea Oncology's highest PB Ratio was 5.82. The lowest was 1.95. And the median was 2.78.
XMAD:PANG's PB Ratio is ranked worse than 60.82% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.005
vs XMAD:PANG: 2.61
During the past 12 months, Pangaea Oncology's average Book Value Per Share Growth Rate was -8.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -7.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 10.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Pangaea Oncology was 86.80% per year. The lowest was -7.60% per year. And the median was 6.25% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Pangaea Oncology PB Ratio Related Terms
Pangaea Oncology PB Ratio Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Pangaea Oncology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Pangaea Oncology (XMAD:PANG) has a PB Ratio of 2.61 as of Jul. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Pangaea Oncology and its competitors. This is near median its historical median of 2.78. Over the past decade, Pangaea Oncology's PB Ratio has ranged from 1.95 to 5.82. According to the industry distribution chart, Pangaea Oncology ranks #118 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 60.8%.
Is Pangaea Oncology's PB Ratio too high?
Pangaea Oncology's current PB Ratio of 2.61 is near median its 10-year median of 2.78. Over the past 10 years, this metric has ranged from a low of 1.95 to a high of 5.82. The Medical Diagnostics & Research industry median PB Ratio is 2.01. Pangaea Oncology's value of 2.61 is 30.2% above this industry median. Based on the distribution chart, Pangaea Oncology ranks #118 out of 194 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Pangaea Oncology has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #118 out of 194 companies for PB Ratio. This places Pangaea Oncology in the lower half of its industry. The industry median PB Ratio is 2.01. Pangaea Oncology's value of 2.61 is 30.2% above this benchmark. Historically, Pangaea Oncology's own PB Ratio has ranged from 1.95 to 5.82 over the past decade. While the company's 10-year median is 2.78 vs. the industry median of 2.01, Pangaea Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.01, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pangaea Oncology's current PB Ratio of 2.61 is 30.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current PB Ratio is 2.61, which is near median its own 10-year median of 2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.18, compared to a current price of €1.55 — trading 28.9% below its estimated fair value. The current PB Ratio is 2.61, which is near median its 10-year median of 2.78 and 30.2% above the Medical Diagnostics & Research industry median of 2.01. Pangaea Oncology's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current PB Ratio is 2.61 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.55 is trading 28.9% below its estimated GF Value™ of €2.18.
GuruFocus considers Pangaea Oncology to be Modestly Undervalued.
Key valuation signals for XMAD:PANG:
PB Ratio: 2.61 (near median its 10-year median of 2.78)
GF Value™: €2.18 vs. price of €1.55 (28.9% below fair value)
Industry Position: 30.2% above the Medical Diagnostics & Research median (#118 of 194)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
61GF Score
Get the complete analysis for XMAD:PANG
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
